alexa Acute Myeloid Leukemia Patients

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Conferences

Clinical Cardiology

San Francisco, USA

Cardiology Summit China

Brussels, Belgium
Acute Myeloid Leukemia Patients

It has been postulated that inhibition of Histone Deacetylase (HDAC) can restore normal acetylation of histone proteins and transcription factors, and to be of benefit in the treatment of cancer. So, this study aimed at assessing the response to histone deacetylase inhibitor valproic acid combined with conventional chemotherapy versus conventional chemotherapy alone in Egyptian Acute Myeloid Leukemia (AML) patients. Thirty newly diagnosed AML patients were divided into 2 groups. Group 1 consisted of 15 AML patients received conventional chemotherapy while group 2 consisted of 15 AML patients received valproic acid 40 mg/kg for 7 days and conventional chemotherapy. Ten healthy persons of matched age and sex were considered group 3 (controls). Serum histone deacetylase activity, vascular endothelial growth factor, basic fibroblast growth factor, tumor necrosis factor α, glutathione S transferase and nuclear factor κB in nuclear extract before and after chemotherapy were measured in all patients and controls. Results revealed better clinical response with no side effects with valproic acid than conventional chemotherapy alone (p=0.021) more


  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger